5 New Drugs Approved for Primary Care: Q4 2022
The end of another quarter means a new list of FDA-approved drugs for conditions treated in primary care. Are you up-to-date? Click through to find out.
The fourth quarter has come and gone, which means Patient Care Online has compiled another list of drugs approved by the US Food and Drug Administration for conditions that are often seen in primary care. In the slides below, find details on the first live microbiota treatment for recurrent Clostridioides difficile infections, a loop diuretic for the at-home treatment of congestion due to fluid overload in patients with chronic heart failure, and 3 more.
Heart failure (HF): Furosemide injection (FUROSCIX®), 80 mg/10 mL, is a loop diuretic indicated for the at-home treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic HF. It is not indicated for emergency situations or in patients with acute pulmonary edema. (Approved 10/07/22, scPharmaceuticals, Inc.)
For full prescribing information, please click here.
Prevention of recurrent Clostridioides difficile infections (rCDI): RBX2660 (Rebyota®), 150 mL, is the first-ever microbiota-based live biotherapeutic indicated for the prevention of rCDI in adults who have completed a course of antibiotic treatment for rCDI. It is prepared from stool donated by qualified healthy individuals and comes as a prepackaged single dose that is administered rectally. It is not indicated for treatment of CDI. (Approved 11/30/22; Ferring Pharmaceuticals Inc.)
For full prescribing information, please click here.
Delaying the Onset of Stage 3 Type 1 Diabetes (T1D): Teplizumab-mzwv Injection (Tzield®), 2 mg/2 mL, a CD3-directed antibody indicated to delay the onset of Stage 3 (T1D in adults and pediatric patients aged 8 years and older with Stage 2 T1D. (Approved 11/17/22; Provention Bio, Inc.)
For full prescribing information, please click here.
Bacterial infection: Vancomycin Hydrochloride for Oral Solution 25 mg (base)/mL and 50 mg (base)/mL. First-time generic approval for Firvanq® (Approved 11/14/22; Alkem Laboratories Ltd.)
Herpes labialis: Penciclovir Cream 1%. First-time generic approval for Denavir® (Approved 11/9/22; Teva Pharmaceuticals USA, Inc.)
